NeonMind
to Present at H.C. Wainwright 23rd
Annual
Global Investment Conference
Vancouver, B.C. - September 8, 2021: NeonMind
Biosciences Inc. (CSE:
NEON) (OTCQB:
NMDBF) (FFE: 6UF) ("NeonMind'' or the "Company"), an integrated drug
development and wellness company focused on the potential
therapeutic uses of psilocybin for treating obesity and weight
management conditions,
today announced that Robert Tessarolo, President and Chief
Executive Officer, will participate in the H.C. Wainwright
23rd Annual Global
Investment Conference, being held virtually starting Monday,
September 13, 2021 at 7:00 a.m. ET.
H.C. Wainwright 23rd Annual Global Investment Conference
Details:
Date: September 13-15, 2021
Registration:
www.hcwevents.com/annualconference
The Company's presentation
will be available on-demand at the start of the conference. In
addition to the Company's presentation, management will be
available to participate in one-on-one meetings with investors who
are registered to attend the conference.
For more information regarding the conference or to schedule a
one-on-one meeting with management, please contact KCSA Strategic
Communications at NeonMind@KCSA.com or your H.C. Wainwright
representatives directly.
About
NeonMind Biosciences Inc.
NeonMind is engaged in
preclinical research to develop potential clinical treatments and
wellness products to address obesity and weight management
conditions and to promote health and wellness. The Company operates
three divisions: (i) a pharmaceutical division engaged in drug
development of psychedelic compounds with two lead psilocybin-based
drug candidates targeting obesity; (ii) a medical services division
focused on launching specialty mental health clinics that integrate
psychedelic therapeutics into traditional psychotherapy settings;
and (iii) a consumer products division that currently sells
mushroom-infused products to promote health and
wellness.
In its pharmaceutical
division, NeonMind has two distinct psilocybin drug development
programs targeting obesity. NeonMind's lead candidate, NEO-001,
employs psilocybin as an agonist at the serotonin 5- HT2A receptor,
which is involved in the hallucinogenic effect of psychedelics. The
Company's second drug candidate, NEO-002, employs low-dose
psilocybin as an agonist at the 5-HT2C receptor, which controls
appetite.
NeonMind established a
medical services division with the goal of launching
NeonMind-branded specialty mental health clinics in Canada that
incorporate evidence-backed innovative treatments to address a
variety of mental health needs.
NeonMind's consumer
division currently sells NeonMind-branded coffee products in the
United States and Canada through NeonMind's direct to consumer
e-commerce platform.
For more information on
NeonMind, go to www.NeonMindBiosciences.com.
For further information, please
contact:
Rob Tessarolo, President & Chief Executive Officer, NeonMind
Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor
Relations:
KCSA Strategic
Communications
Scott Eckstein / Tim
Regan
neonmind@kcsa.com
Tel:
212-896-1210
Media Inquiries:
KCSA Strategic Communications
Annie Graf
neonmind@kcsa.com
Tel: 786-390-2644
The Canadian Securities Exchange has not
reviewed, approved nor disapproved the contents of this news
release.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or NeonMind's future performance. The use of any of the
words "could", "expect", "believe", "will", "projected",
"estimated" and similar expressions and statements relating to
matters that are not historical facts are intended to identify
forward-looking information and are based on NeonMind's current
belief or assumptions as to the outcome and timing of such future
events. Actual future results may differ materially. In particular,
NeonMind's drug development plans, its ability to retain key
personnel, and its expectation as to the development of its
intellectual property and other steps in its preclinical and
clinical drug development constitute forward-looking information.
Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned
not to place undue reliance on forward-looking information. The
statements made in this press release are made as of the date
hereof. NeonMind disclaims any intention or obligation to publicly
update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
may be expressly required by applicable securities
laws.